Northway Biotech would like to announce that UAB Biotechpharma has successfully implemented the project "Development of innovative technologies based on microbial biosynthesis and development of microbial biosynthesis R&D infrastructure" financed under the 2014-2020 European Union funds investment program Priority No. 1 "Promotion of scientific research, experimental development and innovation" No. J05-LVPA-K "Intelektas LT-2" invitation No. 1. For the implementation of the project, Northway Biotech received EUR 9,022,220.10 support from the European Union, while the total project investment reached about EUR 40 million.
During the implementation of the project, Northway Biotech created a modern R&D infrastructure for microbial products development. It will enable the research, creation, and development of future production technologies for microbial products. Together with the partner - the Center for Innovative Medicine, during the project, the manufacturing technology (prototype) was developed of biosimilar long-acting insulin glargine. The implementation of this project will undoubtedly stimulate the entire biomedical and biopharmaceutical sector to develop advanced therapeutic drugs or technologies. It also allows the company to expand its portfolio of products and services, successfully commercialize R&D results and become a competitive world-class company.